The support of the ANR
The GlycoMb project led by Jean-Christophe Fricain (Inserm U1026, University of Bordeaux) has been selected by the ANR (French national agency for research), during the generic call for projects 2020, Committee CE18 - Biomedical innovation. This project involves two Inserm units (U1148 in Paris and U1026 in Bordeaux) as well as the two companies SILAB and SILTISS.
The treatment of segmental bone lesions is a challenge for orthopedic and maxillofacial surgeons who use therapeutic solutions that cause morbidity and high costs to society. This research project is expected to have a medical impact on patient management and an economic impact by reducing the costs associated with multiple surgeries and their complications.